Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - A retrospective database study

International Journal of Clinical Practice

Volumn 67, Issue 12, 2013, Pages 1228-1237

  Jameson, K ^a   Amber, V ^a,b   D'Oca, K ^a   Mills, D ^c   Giles, A ^d   Ambegaonkar, B ^e  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Independent Department   (United States)

^d OXFORD PHARMAGENESIS LTD   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GREAT BRITAIN; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84888058089     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12238     Document Type: Article

References (33)

1. British Heart Foundation. Heart statistics. http://www.bhf.org.uk/ research/heart-statistics.aspx (accessed 14 November 2012).
2. Nichols M, Townsend N, Scarborough P, et al. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
3. Primatesta P, Poulter NR,. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322-5.
4. General Medical Services-contractural changes 2013/2014. http://www.dh.gov.uk/health/2012/12/gp-contract-proposals/ (accessed 19 February 2013).
5. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2): S1-29.
6. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-8.
7. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5): v1-52.
8. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 67. Lipid Modification: Cardiovascular Risk ASsessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: NICE, 2008.
9. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 87. Type 2 Diabetes: the Management of Type 2 Diabetes. London: NICE, 2009.
10. Kannel WB, Castelli WP, Gordon T, McNamara PM,. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1-12.
11. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
12. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010; 376: 333-9.
13. Assmann G, Schulte H,. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733-7.
14. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-10. (Pubitemid 47481452)
15. Kannel WB,. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983; 52: 9B-12B. (Pubitemid 13045217)
16. Sazonov V, Beetsch J, Phatak H, et al. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database. Atherosclerosis 2010; 208: 210-6.
17. Phatak H, Wentworth C, Sazonov V, Burke T,. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009; 202: 225-33.
18. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9. (Pubitemid 36539051)
19. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Anderson KM, Odell PM, Wilson PW, Kannel WB,. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.
21. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 676-83. (Pubitemid 44128440)
22. Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343-51.
23. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301: 831-41.
24. Phatak H, Wentworth C, Burke TA,. Lipid testing among patients beginning statin therapy in general practice in the United Kingdom. Value Health 2008; 11: 933-8.
25. Ambegaonkar B, Chirovsky D, Tse HF, et al. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong. Adv Ther 2012; 29: 427-41.
26. Khovidhunkit W, Silaruks S, Chaithiraphan V, et al. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study. Angiology 2012; 63: 528-34.
27. Pettersson B, Ambegaonkar B, Sazonov V, et al. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health 2010; 10: 737.
28. Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012; 19: 221-30.
29. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
30. Jafri H, Alsheikh-Ali AA, Karas RH,. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800-8.
31. University of Oxford Clinical Trial Service Unit. The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study. http://www.thrivestudy.org/(accessed 24 January 2013).
32. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
33. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 71. Identification and Management of Familial Hypercholesterolaemia. NICE: London, 2008.